The CAP Trial (Cluster randomised trial of PSA testing for prostate cancer), set out to find out if inviting men aged 50-69 for a single prostate specific antigen (PSA) test would help detect high risk cancers earlier and if treating these cancers earlier would mean that men would live longer.
The trial, which involved almost 600 GP practices in the UK and included more than 400,000 men, is the largest trial ever to investigate prostate cancer screening.
The trial compared 189,386 men who were invited to have a one-off PSA test with 219,439 men who were not invited for screening.
Read the trial results here.
Those invited to have a one-off PSA test and who were diagnosed with localised prostate cancer took part in a treatment trial called ProtecT. This randomised control trial investigates the effectiveness of 3 treatments for men diagnosed with localised prostate cancer. To find out more about the ProtecT trial here.
NEWS! CANCER RESEARCH UK AWARD FOR CAP EXTENDS FOLLOW UP UNTIL 2021 Extending follow-up for a median of 15 years will provide up-to-date empirical data to populate lifetime models of screening cost-effectiveness and inform lead time based models of lifetime risks of over-diagnosis and over-treatment where there is little international consensus.
The legal basis for personal data to be obtained and processed for is Article 6 (1) (e) processing is necessary for the performance of a task carried out in the public interest. And the legal basis for health information data is Article 9 (2) (i) processing is necessary for reasons of public interest in the area of public health and Article 9 (2) (j) processing is necessary for reasons of public interest in the area of research. Public interest is defined here as: provide an evidence base for public policy decision-making; provide an evidence base for decisions which are likely to significantly benefit the UK economy, society or quality of life of people in the UK; and to replicate, validate or challenge existing research.